[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568999":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":87,"collaborators":90,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":21,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":44,"whyStopped":21,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Co-use group","E-cigarette and cannabis co-use group",[12,13,14],"Drug: Varenicline Pill","Behavioral: Contingency management","Behavioral: Counseling",[16,22,27],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Varenicline Pill","In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"BEHAVIORAL","Contingency management","Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"Counseling","Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.",[9],[32],{"name":33,"affiliation":5,"role":34},"Erin A McClure, PhD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":21,"email":40},"Elizabeth Chapman, MA, LPC, LAC, AADC","CONTACT","864.898.2992","chapmanb@musc.edu",[42,62,75],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"MUSC Charleston","RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-79.93275,32.77632,{"lat":54,"lon":53},[57,61],{"name":58,"role":38,"phone":59,"phoneExt":21,"email":60},"Ela Williams","843-497-4092","williela@musc.edu",{"name":33,"role":34,"phone":21,"phoneExt":21,"email":21},{"facility":63,"status":44,"city":64,"state":46,"zip":65,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"MUSC Lancaster","Lancaster","29720",{"type":51,"coordinates":67},[68,69],-80.7709,34.72043,{"lat":69,"lon":68},[72],{"name":73,"role":38,"phone":74,"phoneExt":21,"email":40},"Elizabeth Chapman","864-898-2992",{"facility":76,"status":44,"city":77,"state":46,"zip":78,"country":48,"countryCode":49,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Behavioral Health Services of Pickens County","Pickens","29671",{"type":51,"coordinates":80},[81,82],-82.70736,34.88345,{"lat":82,"lon":81},[85],{"name":86,"role":38,"phone":74,"phoneExt":21,"email":40},"Elizabeth Chapman, LPC",{"type":34,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Erin McClure","Associate Professor-Faculty",[91],{"name":92,"class":93},"National Cancer Institute (NCI)","NIH","100568999","phase-4-e-cigarette-cessation-in-adults-who-co-use-cannabis-100568999",false,"NCT06688539","E-cigarette Cessation in Adults Who Co-use Cannabis","A Prospective Trial of Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis","VapeCAT","Inclusion Criteria:\n\n* Between the ages of 18 and 40 years old\n* Use e-cigarettes daily or near daily in the past month\n* Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng\u002Fml)\n* Be interested in quitting use of e-cigarettes\n* Must be willing to take varenicline for the standard 12-week course of treatment\n* Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\\> 50 ng\u002Fml)\n\nExclusion Criteria:\n\n* Any serious or unstable medical\u002Fpsychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance\n* Use of cigarettes on 10+ days in the past 30\n* Currently pregnant or breastfeeding\n* Current use of medications with smoking cessation efficacy\n* Use of any medications that would interfere with varenicline",true,"ALL","18 Years","40 Years",{"count":107,"type":108},105,"ESTIMATED","INTERVENTIONAL",[111],"PHASE4","The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis\u002Fmarijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.",[114,115],"Nicotine Dependence","Tobacco Use Disorder",[117,118,119],"e-cigarettes","cannabis","treatment","2026-06-10",{"date":122,"type":123},"2026-06-12","ACTUAL",{"date":125,"type":123},"2025-02-19",{"date":127,"type":108},"2027-06-01",{"name":5,"class":6},3]